Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors.
The intent of a prescription drug formulary is to shift utilization toward preferred products, but health plans must balance the benefit of these products' lower price with the cost of potential formulary noncompliance. Using proton-pump inhibitors as a model, the authors studied the influence of formulary restrictiveness and drug preference status on formulary noncompliance and marketshare. They found that although drug formulary restrictiveness increases the use of preferred products, it also leads to a high level of formulary noncompliance. The net financial effect on drug spending is ambiguous.
Wang
Y Richard
YR
Health Services Research and Policy Analysis, Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850-5437, USA. y.richard.wang@astrazeneca.com
Pauly
Mark V
MV
D016527:Drug Costs; D005569:Formularies as Topic; D019983:Guideline Adherence; D006801:Humans; D007356:Insurance, Pharmaceutical Services; D010594:Pharmacies; D017494:Proton Pumps / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States
D017494:Proton Pumps